Synthetic nanovaccines for immunotherapy

Min Luo, Layla Z. Samandi, Zhaohui Wang, Zhijian J. Chen, Jinming Gao

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Although vaccination is historically one of the most successful strategies for the prevention of infectious diseases, development of vaccines for cancer and many chronic infections, such as HIV, malaria, and tuberculosis, has remained a challenge. Strong and long-lasting antigen-specific T cell responses are critical for therapy of these diseases. A major challenge in achieving a robust CD8 + T cell response is the requirement of spatio-temporal orchestration of antigen cross-presentation in antigen-presenting cells with innate stimulation. Here, we discuss the development of nanoparticle vaccine (nanovaccine) that modulates the innate immune system and enhances adaptive immunity with reduced toxicity. We address how nanovaccines can integrate multiple functions, such as lymph node targeting, antigen presentation, and stimulation of innate immunity, to achieve a robust T cell response for immunotherapy.

Original languageEnglish (US)
Pages (from-to)200-210
Number of pages11
JournalJournal of Controlled Release
StatePublished - Oct 10 2017


  • Immunotherapy
  • Nanovaccine
  • Synthetic nanoparticle
  • T cell response

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Synthetic nanovaccines for immunotherapy'. Together they form a unique fingerprint.

Cite this